AbbVie’s $100 billion splurge on domestic manufacturing and R&D is continuing to come into focus, this time with a $380 million investment in two new active pharmaceutical ingredient (API) manu | The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results